Business Wire requests that NewsItemId: 20260721835867 N-Zyme Biomedical press release “N-Zyme Biomedical Closes US$4.6 Million Series A Financing to Advance Clinical Development” be killed.

The release was issued prematurely by Business Wire.

A replacement release will be issued at a later date.

"Closing our Series A financing is more than a funding milestone—it’s an important validation of our science, our strategy, and our team’s commitment to transforming the treatment of reflux disease," said Franco Vigile, Co-Founder & Chief Executive Officer